Subject: Eastwood Bio-Medical Canada Inc. - News Release for Dissemination
PDF Document
File: Attachment News Release - Refile MD&A.pdf
EASTWOOD BIO-MEDICAL CANADA INC.
NEWS RELEASE
Eastwood Bio-Medical Canada Inc. Announces Refiling of its Annual and Interim MD&A
November 16, 2026 Richmond, British Columbia Eastwood Bio-Medical Canada Inc.
(TSX-V: EBM) (the "Company") announces that as a result of a review by the British Columbia
Securities Commission (the "BCSC"), the Company is issuing this press release to clarify its
disclosure.
With respect to the Company's annual management's discussion and analysis for the year ended
October 31, 2025 (the "Annual MD&A") and its interim management's discussion and analysis
for the nine month period ended July 31, 2026 (the "Interim MD&A", and together with the
Annual MD&A, the "Affected Filings"), the BCSC has concluded that the Affected Filings lack
sufficient discussion as per the requirements of Form 51-102F1. As a result, the Company has
amended and refiled the Affected Filings.
The Affected Filings clarify the Company's supply and manufacturing arrangements, expand the
disclosure of related-party relationships and balances, and strengthen the discussion of liquidity
and financing needs. They also provide more detail on the factors affecting revenue and gross
margin, add disclosure of recent strategic agreements, and make minor corrections and formatting
updates throughout.
The amended and restated Affected Filings have been filed on SEDAR+ at www.sedarplus.ca. The
amended and restated Affected Filings replace and supersede the corresponding financial
statements and MD&A previously filed by the Company. Readers should rely only on the amended
and restated Affected Filings now available on SEDAR+.
For further information, please contact:
Eastwood Bio-Medical Canada Inc.
Yunji Kim, President and Chief Financial Officer.
Telephone: (604) 247-2100
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Word Document
File: '\\swfile\EmailIn\20261116 135402 Attachment News Release - Refile MD&A.docx'
© 2026 Canjex Publishing Ltd. All rights reserved.